DC Brands International, Inc. (PINK:HRDN) reached up 280% in morning trading to $.0019 with 75M shares traded. DC Brands International presently specializes in the manufacturing of its functional beverages and health products. Established in 1998, DC Brands began producing a number of lines of energy drinks in 2005. DC Brands then purchased the assets of H.A.R.D. Nutrition and began its quest to produce a new health line of products. DC Brands has recently announced the release of its new H.A.R.D. Nutrition Functional Water Systems, which it expects will revolutionize the functional beverage category. DC Brands International, Inc. (OTC:HRDN.PK - News) today announces that it has entered into a contract with Dixon Marketing, Inc. (DMI) for distribution into the military resale system, and has received an initial Purchase Order to launch the relationship.
Himax Technologies, Inc. (Nasdaq:HIMX) reached up 19.27% in morning trading to $2.29 with 1M shares traded. Himax Technologies, Inc. is a fabless semiconductor solution provider dedicated to display imagine processing technologies. Himax is a worldwide market leader in display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, car navigation, and many other consumer electronics devices. Additionally, Himax designs and provides controllers for touch sensor displays, LCOS micro-displays used in palm-size projectors and head-mount displays, LED driver ICs, power management ICs, and chipsets for TVs and monitors. The company also offers digital camera solutions, including CMOS image sensors and wafer level optics, which are used in a wide variety of applications such as mobile phone, tablet, laptop, TV, PC camera, automobile, security and medical devices. Himax Technologies, Inc. (Nasdaq:HIMX - News) today announced that it expects its first quarter revenues, gross margin and EPS to exceed the Company's previously announced guidance on February 13, 2012.
BELLUS Health Inc. (PINK:BLUS) reached up 47.50% in morning trading to $.059 with 800K shares traded. BELLUS Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company, in collaboration with its partner, Celtic Therapeutics, is currently advancing its novel drug candidate KIACTA™, through phase III trials for treatment of AA Amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and eventually death. AA Amyloidosis affects approximately 50,000 individuals in the United States , Europe and Japan . BELLUS Health Inc. (TSX: BLU.TO - News) today announced that it has entered into a strategic partnership and financing with Pharmascience Inc. ("Pharmascience") whereby Pharmascience will pay a total of $17.25 million to BELLUS Health, including $8.15 million in non-dilutive capital and a $9.1 million investment for a 10.4% ownership stake in a new public company ("New BELLUS"). The partnership will be put in place through a plan of arrangement, under which 89.6% of New BELLUS will be owned by securityholders of BELLUS Health.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
About PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at publisher@pennytrader.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE
